WO2023006565A1 - Procédé de préparation de formulations d'édaravone - Google Patents

Procédé de préparation de formulations d'édaravone Download PDF

Info

Publication number
WO2023006565A1
WO2023006565A1 PCT/EP2022/070466 EP2022070466W WO2023006565A1 WO 2023006565 A1 WO2023006565 A1 WO 2023006565A1 EP 2022070466 W EP2022070466 W EP 2022070466W WO 2023006565 A1 WO2023006565 A1 WO 2023006565A1
Authority
WO
WIPO (PCT)
Prior art keywords
edaravone
formulation
ppm
oxygen
process according
Prior art date
Application number
PCT/EP2022/070466
Other languages
English (en)
Inventor
José Andrés LOZANO VELILLA
Montserrat GARCÍA ROVIRA
Ernesto DURAN LÓPEZ
Original Assignee
Medichem, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medichem, S.A. filed Critical Medichem, S.A.
Publication of WO2023006565A1 publication Critical patent/WO2023006565A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Definitions

  • This invention relates to a process for preparing an aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof with low contents of impurities that is stable during storage, transportation, and use.
  • Edaravone is the international commonly accepted non-propietary name (INN) for 3-methyl-1-phenyl-2-pyrazolin-5-one, and has an empirical formula of C10H10N2O and a molecular weight of 174.20 g/mol.
  • Edaravone sold as under the brand names Radicava or Radicut, is a medication used to help with recovery following a stroke and to treat amyotrophic lateral sclerosis (ALS).
  • ALS amyotrophic lateral sclerosis
  • Edaravone when given to patients intravenously it is supplied in the form of ampoules or bags containing the injectable aqueous solution of edaravone.
  • the US commercial injectable formulation Radicava is an aqueous solution of edaravone, which is administered intravenously by infusion or drip. It is supplied in a polypropylene bag, which is further overwrapped with polyvinyl alcohol overpouch.
  • the US commercial injectable formulation Radicava contains the following excipients: L-cysteine hydrochloride hydrate, sodium bisulfite, sodium chloride and phosphoric acid and sodium hydroxide to adjust the pH to about 4.
  • Edaravone is extremely stable in a solid state, but aqueous solutions of edaravone have been found to be unstable.
  • Several impurities have been disclosed to be present in aqueous solutions of edaravone.
  • China Licensed Pharmacist Aug 2014, Vol. 11 No.8 discloses several impurities present in Radicut, aqueous solution of edaravone, being Impurity I, 2-(3- methyl-5-oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)-2-sulfopropanoic acid, one of the disclosed impurities:
  • Impurity I CN106316957A and CN110090225A disclose the Impurity I as an impurity present in aqueous solutions of edaravone which contain sodium bisulfite as excipient.
  • CN106316957A describes a preparation method for the Impurity I.
  • CN102336710A also discloses the preparation of the Impurity I.
  • This impurity is supposed to be formed due to the presence of sodium bisulfite, which is used as stabilizer in the aqueous pharmaceutical formulations of edaravone.
  • HSOT bisulfite anions
  • the present invention provides a process for preparing an aqueous formulation comprising edaravone or a pharmaceutically acceptable salt thereof and bisulfite anions (HSOT), wherein the process comprises: a) providing an aqueous formulation comprising i) edaravone or a pharmaceutically acceptable salt thereof and ii) bisulfite anions, and controlling the oxygen content of said formulation to be less than 1 ppm of oxygen, and b) heat sterilizing the formulation resulting from step a).
  • HSOT bisulfite anions
  • the aqueous formulations prepared according to the process of the present invention are preferably pharmaceutical formulations, namely the aqueous formulations prepared according to the process of the present invention are safe, non-toxic and acceptable for human therapeutic use.
  • the aqueous formulations prepared according to the process of the present invention are preferably injectable pharmaceutical formulations.
  • the oxygen content of the formulation is controlled to be less than 0.5 ppm of oxygen.
  • the objective of the above-described process is to have an aqueous formulation comprising edaravone or a pharmaceutically acceptable salt thereof, bisulfite anions and less than 1 ppm of oxygen, preferably less than 0.5 ppm of oxygen, (step a), which is then subjected to heat sterilization (step b).
  • the invention involves ensuring that the oxygen content of the aqueous formulation just before the sterilization step b) is less than 1 ppm, preferably less than 0.5 ppm of oxygen. This may be achieved through the following steps:
  • aqueous formulation comprising i) edaravone or a pharmaceutically acceptable salt thereof and ii) bisulfite anions having an oxygen content of less than 1 ppm, preferably less than 0.5 ppm of oxygen.
  • step 1) optionally further controlling the oxygen content of the environment during the handling of the aqueous formulation of step 1).
  • the provision of the aqueous formulation of step 1) may be achieved by one or more of the following steps: i) controlling the oxygen content of the water used to prepare the aqueous formulation, ii) controlling the oxygen content of the environment in which the aqueous formulation is prepared, iii) taking active measures to reduce the oxygen content of the aqueous formulation if said formulation has an oxygen content of 1 ppm or more.
  • the oxygen content is also controlled during the heat-sterilization.
  • the aqueous formulation comprising edaravone or a pharmaceutically acceptable salt thereof, bisulfite anions and less than 1 ppm of oxygen, preferably less than 0.5 ppm of oxygen, (step a)), which is then subjected to heat sterilization (step b) is an aqueous solution.
  • the above-mentioned formulation (resulting from step a)) is prepared using water which has a content of less than 1 ppm of oxygen, preferably less than 0.5 ppm of oxygen, (i.e. deoxygenated water) while controlling the oxygen of the environment to prevent that oxygen is absorbed by the aqueous formulation (which could yield to the aqueous formulation having 1 or more ppm of oxygen, for example from 1 to 9 ppm of oxygen).
  • the control of oxygen content takes place before the actual preparation of the aqueous formulation (by using deoxygenated water), during the preparation of the aqueous formulation, during the handling of the aqueous formulation and during sterilization (by using an environment poor in, or free of oxygen).
  • water having a content of 1 or more ppm of oxygen is used to prepare the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof and bisulfite anions. Then, after obtaining said aqueous formulation, the content of oxygen is reduced to obtain an aqueous formulation having less than 1 ppm of oxygen, more preferably less than 0.5 ppm of oxygen, before heat-sterilization.
  • deoxygenated water having a content of less than 1 ppm of oxygen, preferably of less than 0.5 ppm of oxygen
  • no measure or not all the measures to control the oxygen content of the environment are taken.
  • the resulting aqueous formulation will very likely have an oxygen content of 1 ppm or more, for example from 1 to 9 ppm of oxygen, due to the absortion of oxygen from the environment. For this reason, after obtaining the aqueous formulation, the content of oxygen is reduced to obtain an aqueous formulation having less than 1 ppm of oxygen, preferably less than 0.5 ppm of oxygen, before heat- sterilization.
  • Any method of reducing oxygen of an aqueous formulation can be used to control the oxygen content of the aqueous formulation to be less than 1 ppm of oxygen, preferably to be less than 0.5 ppm of oxygen.
  • the method of reducing oxygen comprises placing the aqueous formulation together with an oxygen scavenger in a closed environment for a duration of time sufficient to reduce the oxygen content of the aqueous formulation to the desired levels.
  • the aqueous formulation may be in direct contact with the oxygen scavenger or, even preferably, separated from the scavenger by an oxygen-permeable material.
  • An alternative embodiment of reducing oxygen is placing the aqueous formulation in an oxygen-free (or oxygen-poor) environment and bubbling an inert gas (such as nitrogen or argon) through the aqueous formulation.
  • an inert gas such as nitrogen or argon
  • the container preferably a plastic bag, more preferably a multi-layered plastic bag, which contains the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof having more than 1 ppm of oxygen, for example from 1 to 9 ppm of oxygen, is placed, preferably under an inert atmosphere of argon or nitrogen, preferably of nitrogen, in an overpouch, preferably an aluminum overpouch, provided with an oxygen scavenger (e.g.
  • the handling of the aqueous formulation while controlling its oxygen content may include, for example, transporting the aqueous formulation and/or filling the aqueous formulation in a container, for example a plastic bag. It is possible to control the oxygen content of the formulation during the handling steps by working on an environment poor in, or free of oxygen and/or by flushing with argon or nitrogen the headspace of the container filled with the aqueous formulation.
  • the authors of the present invention have found that the formation of impurities, concretely of the Impurity I, is surprisingly and drastically reduced when the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof comprising bisulfite anions, preferably a bisulfite salt, which is subjected to the heat-sterilization, contains less than 1 ppm of oxygen, preferably less than 0.5 ppm of oxygen,
  • phenylhydrazine which is a genotoxic impurity
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof comprising bisulfite anions which is subjected to the heat-sterilization contains less than 1 ppm of oxygen, preferably less than 0.5 ppm of oxygen.
  • the amount of oxygen in the aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof as defined in the present invention refers to the amount of dissolved oxygen in said formulations.
  • the bisulfite anions (HSOT) present in the formulations obtainable by the process of the present invention may be added in the form of any compound or mixture of compounds yielding in water solution said bisulfite anions (HSOT) ⁇
  • Non-limiting examples of compounds which yield bisulfite anions (HSO 3 ) in aqueous solutions are a salt of bisulfite and a cation, preferably a salt selected from the group consisting of sodium bisulfite, potassium bisulfite and mixtures thereof; a salt of metabisulfite and a cation, preferably a salt selected from sodium metabisulfite, potassium metabisulfite and mixtures thereof; a salt of sulfite and a cation, preferably a salt selected from sodium sulfite, potassium sulfite and mixtures thereof; and mixtures of any one of these salts.
  • the source of bisulfite ion is sodium bisulfite, sodium metabisulfite or mixtures thereof.
  • the bisulfite anions (HSO3) are present in the form of sodium bisulfite.
  • Bisulfite anions have been used as excipient, concretely as stabilizer in aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof.
  • HSO 3 Bisulfite anions
  • its presence entails the formation of Impurity I, mainly during the heat- sterilization step of the aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof.
  • the process of the present invention allows to use bisulfite anions (HSOT) in the aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof, thus protecting edaravone from degradation, while reducing the formation of Impurity I whose formation is directly linked to the presence of bisulfite anions (HSOT) when the aqueous formulation is subjected to heat-sterilization.
  • HSOT bisulfite anions
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof obtained by the process of the present invention after step b) is a sterilized aqueous formulation, preferably an injectable formulation, namely a pharmaceutical injectable formulation.
  • excipients used in the present invention must be suitable for use in contact with tissues or organs of humans and/or animals without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications consistent with a reasonable benefit/risk ratio.
  • “Pharmaceutically acceptable salt” as used herein refers to any salt that is useful for preparing a pharmaceutical formulation and it is tolerated physiologically, i.e. , it is non- toxic, when used for therapeutic purposes in humans and/or animals.
  • pharmaceutically acceptable salts mention may be made of salts with mineral acids such as hydrochloric acid, sulfuric acid, hydrobromide, phosphoric acid, and the like; salts with organic acids such as methanesulfonic acid, p-toluenesulfonic acid, acetic acid, oxalic acid, citric acid, malic acid, fumaric acid, and the like; salts with alkali metals such as sodium, potassium, and the like; salts with alkaline earth metals such as magnesium, and the like; and salts with amines such as ammonia, ethanolamine, 2- amino-2-methyl-1 -propanol, and the like.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof, comprising bisulfite anions (HSOT) obtained according to the process of the present invention after step b) contains less than 0.10 % (area) of the Impurity I, preferably less than 0.05 % (area) of the Impurity I, more preferably less than 0.03 % (area) of the Impurity I, when analyzed by a column chromatography method for purity, for example a HPLC or UHPLC method.
  • the aqueous formulation of edaravone or a pharmaceutically salt thereof, comprising bisulfite anions (HSOT) obtained according to the process of the present invention after step b) is stable for at least six months at 40° C ⁇ 2° C and a relative humidity of 75% and for at least six months, preferably for at least nine months, more preferably for at least twelve months, more preferably for at least twenty-four months, even more preferably for at least thirty-six months, at 25° C ⁇ 2° C and a relative humidity of 60%.
  • stable means that the amount of each impurity, concretely of the Impurity I, is maintained in amounts less than 0.25% (area), preferably less than 0.20% (area), more preferably less than 0.15% (area), even more preferably less than 0.10 (area), when analyzed by a column chromatography method for purity, for example a HPLC or UHPLC method.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof, comprising bisulfite anions (HSOT) obtained according to the process of the present invention after step b) contains less than 300 ppm, preferably less than 200 ppm, more preferably less than 150 ppm, even more preferably less than 100 ppm of phenylhydrazine, when analyzed by a column chromatography method, for example a HPLC or UHPLC method.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof, which comprises bisulfite anions (HSOT), preferably in the form of sodium bisulfite, which is subjected to the heat-sterilization is preferably contained in a container which can be a glass or a plastic ampoule or a plastic bag.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof, which comprises bisulfite anions (HSOT), preferably in the form of sodium bisulfite, and which is subjected to the heat-sterilization step is contained in a plastic bag, preferably in a multi-layered plastic bag, more preferably in a three, four, five or six-layer plastic bag.
  • any multi-layered plastic bag known in the art to be suitable for storing aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof can be used in the process for preparing aqueous formulations of edaravone or a pharmaceutically salt thereof of the present invention.
  • Non-limiting examples of the plastic bags used in the present invention are bags equivalent or equal to those disclosed in JP6863845B2, W02009066752A1 , W02010016404A1, JP4596124B2, JP2018192643A1,
  • W02008001496A 1 WO201079693A1, WO2019151532A1 or WO2019159967A1.
  • the multi-layered plastic bag comprises at least one layer, which comprises a cycloolefin polymer.
  • Cycloolefin polymers are materials that contain, or are made from, at least one cyclic monomer. Cycloolefin polymers include cyclic olefin polymers (COP) and cyclic olefin copolymers (COC).
  • the multi-layered plastic bag comprises at least one layer, which comprises at least one cyclic olefin polymer (COP).
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof which is subjected to the heat-sterilization is contained in a multi-layered plastic bag which is a three-layer plastic bag which comprises: an innermost layer which comprises at least one cyclic olefin polymer (COP); a resin layer disposed on the innermost layer and an outer layer disposed on the resin layer which might be made of polypropylene and/or polyethylene.
  • the adhesive resin layer may be composed of linear low-density polyethylene, styrene- based elastomer and polypropylene-based resin.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof which is subjected to the heat-sterilization is contained in Fujimori’s/Zacros Nip ® - ⁇ Bag or Fujimori’s/Zacros MediTect ® IV Bag.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof which is subjected to the heat-sterilization is contained in a multi-layered plastic which is a five-layer plastic bag which comprises: an innermost layer made of polypropylene and/or polyethylene; an adhesive layer disposed on the innermost layer; a layer made of at least one cyclic olefin polymer (COP) disposed on the adhesive layer; an adhesive layer disposed on the cyclic olefin polymer (COP) layer and an outermost layer disposed on the adhesive layer made of polypropylene and/or polyethylene.
  • the adhesive resin layer may be composed of linear low-density polyethylene and polypropylene-based resin.
  • deoxygenated water for example “deoxygenated water for injection” as used herein means that the water, for example the water for injection, contains less than 1 ppm of oxygen, preferably less than 0.5 ppm of oxygen.
  • Deoxygenated water preferably deoxygenated water for injection
  • an inert gas such as argon or nitrogen, preferably nitrogen, at room temperarute, i.e. , at 25 ⁇ 5°C
  • the aqueous formulation is filled in a container, preferably a plastic bag, more preferably a multi layered plastic bag, under an inert atmosphere of argon or nitrogen, preferably of nitrogen and the headspace is flushed with an inert gas such as argon or nitrogen, preferably nitrogen.
  • an inert gas such as argon or nitrogen, preferably nitrogen.
  • the oxygen content in the headspace atmosphere after flushing with an inert gas is less than 10% (w/w), preferably less than 5% (w/w), for example 2%-3% (w/w).
  • the control of oxygen is carried out by placing the container, preferably a plastic bag, more preferably a multi-layered plastic bag, which contains the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof having more than 1 ppm of oxygen, for example from 1 to 9 ppm of oxygen, preferably under an inert atmosphere of argon or nitrogen, preferably of nitrogen, in an overpouch, preferably an aluminum overpouch, provided with an oxygen scavenger (e.g.
  • the packaging formed by the container preferably the plastic bag, more preferably the multi-layered plastic bag, which contains the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof, having more than 1 ppm of oxygen, for example from 1 to 9 ppm of oxygen, which is placed in the overpouch, preferably an aluminum overpouch, is kept, preferably at 25 ⁇ 5 °C, for a time from 5 to 20 days, for example 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 days, more preferably fora time from 7 to
  • any overpouch i.e., any bag, which is non-permeable to oxygen and suitable for protecting formulations, preferably aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof, can be used in the process of the present invention.
  • Non-limiting examples of materials which may form part of the overpouch include silica- or alumina-vapor-deposited polyethylene terephthalate film, silica- or alumina-vapor-deposited nylon film, aluminum-vapor-deposited polyethylene terephthalate, aluminum-vapor-deposited nylon, aluminum foil, ethylene-vinyl-alcohol, poly(vinyl alcohol), polyvinylidene chloride and mixtures thereof.
  • aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof contained in a container preferably a plastic bag, more preferably a multi-layered plastic bag, which is placed in an overpouch, preferably an aluminum overpouch, provided with an oxygen scavenger (e.g. Mitsubishi Gas Chemical Company, Inc, “Ageless” or Dry Pak oxygen scavangers), has a content of oxygen of less than 1 ppm, preferably less than 0.5 ppm, the overpouch, preferably the aluminum overpouch, and the oxygen scavenger (e.g.
  • the container preferably the plastic bag, more preferably the multi layered plastic bag, which contains the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof, having a content of oxygen of less than 1 ppm, preferably less than 0.5 ppm, is placed in a second overpouch, preferably a second aluminum overpouch, and the headspace between the container and the second overpouch is totally or partially removed under vacuum before heat- sterilization.
  • the container preferably the plastic bag, more preferably the multi layered plastic bag, which contains the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof, having a content of oxygen of less than 1 ppm, preferably less than 0.5 ppm, is placed in a second overpouch, preferably a second aluminum overpouch, and the headspace between the container and the second overpouch is totally or partially removed under vacuum before heat- sterilization.
  • the heat-sterilization of the aqueous formulation resulting from step a) having less than 1 ppm of oxygen, preferably less than 0.5 ppm of oxygen, which is contained in a container which is a plastic bag, preferably a multi-layered plastic bag, can be performed under vacuum or under an inert atmosphere, for example an argon or nitrogen atmopshere, preferably under a nitrogen atmosphere.
  • vacuum means under reduced pressure, i.e., a pressure lower than 760 mmHg or 101.3 kPa.
  • the heat-sterilization of the aqueous formulation resulting from step a) having less than 1 ppm of oxygen, preferably less than 0.5 ppm of oxygen, which is contained in a container which is a plastic bag, preferably a multi-layered plastic bag, being this container placed in an overpouch, preferably an aluminum overpouch, is performed under vacuum or under an inert atmosphere, for example an argon or nitrogen atmosphere, preferably under a nitrogen atmosphere, or under atmospheric air.
  • the heat-sterilization is for 5 minutes to 30 minutes at 115°C to 125°C. For example, for 5 minutes at 123°C, for 10 minutes at 123°C or for 15 minutes at 121°C.
  • the overpouch preferably an aluminum overpouch
  • the container preferably a plastic bag, more preferably a multi-layered plastic bag
  • an overpouch preferably a transparent plastic overpouch, preferably a transparent multi-layered overpouch or bag
  • an oxygen scavenger for example Dry Pak ® oxygen absorber
  • an oxygen indicator for example, Dry Pak ® oxygen indicator.
  • Any overpouch which is non-permeable to oxygen and suitable for protecting formulations, preferably aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof, can be used after heat-sterilization in the process of the present invention.
  • the transparent multi-layered plastic ovepouch might be a three-layer, four-layer, five-layer or six-layer overpouch.
  • materials which may form part of this transparent overpouch include polypropylene, polyethylene, poly(vinyl alcohol), nylon and silicified vaporized polyethylene terephthalate.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof prepared according to the process of the present invention may contain other excipients apart from the source of bisulfite, preferably in the form of sodium bisulfite.
  • excipients are stabilizers, surfactants, buffers, solubilizers, antioxidants, antifoamers, tonicity agents, emulsifiers, suspending agents, preservatives, soothing agents, solubilizers, solubilizing adjuvants and mixtures thereof.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof which is obtained according to the process of the present invention is an aqueous injectable formulation of edaravone or a pharmaceutically salt thereof comprising as excipients sodium bisulfite, sodium chloride, L-cysteine hydrochloride hydrate and sodium hydroxide and/or phosphoric acid to adjust the pH to about 4.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof preferably an aqueous injectable formulation of edaravone or a pharmaceutically acceptable salt thereof, which is obtained according to the process of the present invention has an edaravone concentration preferably between 0.06 mg/ml_ to 1.0 mg/ml_, for example 0.3 mg/ml_ and 0.6 mg/ml_, and the liquid volume of the aqueous pharmaceutical formulations is preferably 50 ml_ to 500 ml_, for example 100 mL.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof preferably an aqueous injectable formulation of edaravone or a pharmaceutically acceptable salt thereof, which is obtained according to the process of the present invention contains bisulfite anions, preferably in the form of sodium bisulfite, in an amount from 0.1 mmol/L to 10.0 mmol/L of bisulfite anions, preferably from 0.5 mmol/L to 5 mmol/L, more preferably between about 1.9 mmol/L and about 2 mmol/L.
  • bisulfite anions preferably in the form of sodium bisulfite
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof preferably an aqueous injectable formulation of edaravone or a pharmaceutically acceptable salt thereof, which is obtained according to the process of the present invention contains L-cysteine hydrochloride hydrate in an amount from 0.01 mg/mL to 1.0 mg/mL, preferably from 0.05 mg/mL to 0.5 mg/mL, more preferably about 0.1 mg/mL.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof preferably an aqueous injectable formulation of edaravone or a pharmaceutically acceptable salt thereof, which is obtained according to the process of the present invention contains sodium chloride in an amount from 1.0 mg/mL to 20.0 mg/mL, preferably from 5.0 mg/mL to 10.0 mg/mL, more preferably about 8.7 mg/mL.
  • the aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof which is obtained according to the process of the present invention contains: i) sodium bisulfite, in an amount from 0.1 mmol/L to 10.0 mmol/L of bisulfite anions, preferably from 0.5 mmol/L to 5 mmol/L, more preferably about 1.9 mmol/L and about 2 mmol/L; ii) L-cysteine hydrochloride hydrate in an amount from 0.01 mg/mL to 1.0 mg/mL, preferably from 0.05 mg/mL to 0.5 mg/mL, more preferably about 0.1 mg/mL; iii) sodium chloride in an amount from 1.0 mg/mL to 20.0 mg/mL, preferably from 5.0 mg/mL to 10.0 mg/mL, more preferably about 8.
  • All the oxygen contents for example in the deoxygenated water, preferably deoxygenated water for injection, in the aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof or in the the headspace of the container, preferably a plastic bag, more preferably a multi-layered plastic bag, containing the aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof, can be measured with an oximeter, for example the Mettler Toledo oximeter SevenGo pro.
  • an oximeter for example the Mettler Toledo oximeter SevenGo pro.
  • Another aspect of the present invention provides an aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof, more preferably an aqueous injectable formulation of edaravone or a pharmaceutically acceptable salt thereof, obtainable according to the process of the present invention.
  • obtainable is used herein for defining aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof, more preferably an aqueous injectable formulation of edaravone or a pharmaceutically acceptable salt thereof, by its preparation process.
  • aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof more preferably an aqueous injectable formulation of edaravone or a pharmaceutically acceptable salt thereof, by its preparation process.
  • the expressions “obtainable”, “obtained” and similar equivalent expressions are used interchangeably and, in any case, the expression “obtainable” encompasses the expression “obtained”.
  • aqueous formulation of edaravone or a pharmaceutically acceptable salt thereof can be used for the treatment of stroke and motor neuron diseases such as amyotrophic lateral sclerosis (ALS), spinal muscle atrophy (SMA), progressive bulbar palsy, primary lateral sclerosis (PLS), or arthrogryposis multiplex congenita (AMC).
  • stroke and motor neuron diseases such as amyotrophic lateral sclerosis (ALS), spinal muscle atrophy (SMA), progressive bulbar palsy, primary lateral sclerosis (PLS), or arthrogryposis multiplex congenita (AMC).
  • the method for determining the purity (i.e. assay) and the impurities (for example Impurity I) comprises any column chromatography method, for example an HPLC or UHPLC method, used to determine the purity and the impurities (for example Impurity I) of aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof.
  • the chromatographic method for determining the purity and the impurities (for examples Impurity I) comprises the UHPLC method used in the present invention.
  • the % area of a specific compound, for example of Impurity I, as used in the present invention is calculated as follows: the area of the specific compound, for example of Impurity I, of the chromatograpm of the column chromatography method for purity, preferably the UHPLC chromatogram obtained as defined in the UHPLC method for purity of the present invention, is divided by the total area of the peaks in the chromatogram of the column chromatography method for purity, preferably of the UHPLC chromatogram obtained as defined in the UHPLC method for purity of the present invention. The value obtained is then multiplied by 100.
  • the method for determining the phenylhydrazine comprises any column chromatography method, for example an HPLC or UHPLC method, used to determine the phenylhydrazine of aqueous formulations of edaravone or a pharmaceutically acceptable salt thereof.
  • the chromatographic method for determining the phenylhydrazine comprises the HPLC method used in the present invention.
  • the present invention relates to the use of a formulation of edaravone or a pharmaceutically salt thereof obtainable or obtained by the process described above for the treatment of stroke and motor neuron diseases such as amyotrophic lateral sclerosis (ALS), spinal muscle atrophy (SMA), progressive bulbar palsy, primary lateral sclerosis (PLS), or arthrogryposis multiplex congenita (AMC).
  • ALS amyotrophic lateral sclerosis
  • SMA spinal muscle atrophy
  • PLS primary lateral sclerosis
  • AMC arthrogryposis multiplex congenita
  • the present invention relates to a formulation of edaravone or a pharmaceutically salt thereof obtainable or obtained by the process described above for use in the treatment of stroke and motor neuron diseases such as amyotrophic lateral sclerosis (ALS), spinal muscle atrophy (SMA), progressive bulbar palsy, primary lateral sclerosis (PLS), or arthrogryposis multiplex congenita (AMC).
  • ALS amyotrophic lateral sclerosis
  • SMA spinal muscle atrophy
  • PLS primary lateral sclerosis
  • AMC arthrogryposis multiplex congenita
  • the present invention relates to the use of a formulation of edaravone or a pharmaceutically salt thereof obtainable or obtained by the process described above for the manufacture of a medicament for the treatment of stroke and motor neuron diseases such as amyotrophic lateral sclerosis (ALS), spinal muscle atrophy (SMA), progressive bulbar palsy, primary lateral sclerosis (PLS), or arthrogryposis multiplex congenita (AMC).
  • ALS amyotrophic lateral sclerosis
  • SMA spinal muscle atrophy
  • PLS primary lateral sclerosis
  • AMC arthrogryposis multiplex congenita
  • the present invention relates to the a method for the treatment of stroke and motor neuron diseases such as amyotrophic lateral sclerosis (ALS), spinal muscle atrophy (SMA), progressive bulbar palsy, primary lateral sclerosis (PLS), or arthrogryposis multiplex congenita (AMC) by administration to a subject in need thereof of a formulation of edaravone or a pharmaceutically salt thereof obtainable or obtained by the process described above.
  • stroke and motor neuron diseases such as amyotrophic lateral sclerosis (ALS), spinal muscle atrophy (SMA), progressive bulbar palsy, primary lateral sclerosis (PLS), or arthrogryposis multiplex congenita (AMC)
  • the chromatographic separation was carried out in UHPLC apparatus with an UV- Visible detector (244 nm).
  • the mobile phase B was: - 90% HPLC-grade Methanol
  • the chromatograph was programmed as follows: initial 5.0 min isocratic 100% mobile phase A; 5.0-9.4 min linear gradient to 95% mobile phase A; 9.4-37.5 min linear gradient to 80% mobile phase A; 37.5-50.0 min linear gradient to 50% mobile phase A; 50.0-62.5 min isocratic 50% mobile phase A; 62.5-64.0 min linear gradient to 100% mobile phase A; 64.0 to 75.0 min isocratic 100% mobile phase A.
  • Standard Solution 100 % (about 300 mg/mL Edaravone): 50.0 mg of edaravone working standard were weighted in a 50.0 mL volumetric flask, diluted with diluent A and sonicated for 5 minutes. 6.0 mL of this solution was diluted to 20.0 mL with diluent B. This solution was filtered through 0.22 pm PVDF filter.
  • Test solution the sample from the plastic bag was withdrawn and directly injected without the need of filtration.
  • HPLC method used for analysing the amount of phenylhydrazine in the injectable aqueous pharmaceutical formulations of edaravone or a pharmaceutically acceptable salt thereof
  • the chromatographic separation was carried out in HPLC apparatus with PDA detector (Wavelength: 232 nm).
  • the chromatograph was programmed as follows: initial 18.5 min isocratic 90% mobile phase A; 18.5-21.0 min linear gradient to 60% mobile phase A; 21.0-26.0 min isocratic 60% mobile phase A; 26.0-28.0 min linear gradient to 90% mobile phase A; 28.0-35.0 min isocratic 90% mobile phase A.
  • the flow rate was 1.0 mL/min.
  • a calibration curve was calculated from the analysis of different Standard solutions of phenylhydrazine concentration from 16 to 1500 ppm of phenylhydrazine with respect to edaravone which were prepared from the stock Standard solution.
  • Test solution 30 mg/100mL Dose (preparation for approximately 300 pg/mL of Edaravone): 1.0 mL of the sample from the plastic bag was taken into a 5.0 mL volumetric flask and diluted up with diluent B.
  • Example 1 Preparation of the aqueous formulation of edaravone 0.3 mg/mL of the following formula:
  • edaravone a source of sodium bisulfite (consisting of a mixture of ⁇ 10% (w/w) sodium bisulfite + > 90% (w/w) sodium metabisulfite yielding 20.00 mg of sodium bisulfite), sodium chloride and L-cysteine hydrochloride hydrate were dissolved in deoxygenated water for injection containing less than 1 ppm of oxygen.
  • the pH of the aqueous solution was adjusted to about 4 with the addition of sodium hydroxide 1N and phosphoric acid 85%.
  • the aqueous solution was filtered through a single PVDF 0.22 pm sterilizing filter and the filtered solution was filled inside a grade C isolator and into a non-sterile 100 mL three-layer plastic bag (Fujimori’s Nip ® solution Bags for Pharmaceuticals).
  • the headspace of the filled bags was flushed with nitrogen and then were sealed with a stopper and cap that was welded into place by using a Branson ultrasonic welder.
  • aqueous edaravone solution was analyzed before sterilization (see table 1). Samples were collected for the bulk sample, i.e., before the filling of the bags, and at end of the filling.
  • Table 2 The results of the oxygen content of the aqueous edaravone solutions are depicted in Table 2:
  • the aqueous edaravone solution was analyzed after heat-sterilization. Samples of three bags were analyzed by duplicate.
  • Table 3 shows the average results after heat-sterilization of the aqueous formulation of edaravone having about 1.78 ppm of oxygen.
  • Impurity I As it can be observed around 0.12-0.14% (area) of Impurity I is formed when the aqueous formulation of edaravone containing about 1.78 ppm of oxygen is autoclaved.
  • Table 4 shows the average results after heat-sterilization of the aqueous formulation of edaravone having about 0.39 ppm of oxygen.
  • Example 2 Preparation of aqueous formulation of edaravone 0.3 mg/mL (90 L batch size) according to the process of the present invention (comprising the step of heat- sterilizing an aqueous formulation of edaravone containing less than 1 ppm of oxygen):
  • edaravone a source of sodium bisulfite (sodium metabisulfite yielding 20.00 mg of sodium bisulfite), sodium chloride and L-cysteine hydrochloride hydrate were dissolved in deoxygenated water for injection containing less than 1 ppm of oxygen.
  • the pH of the aqueous solution was adjusted to about 4 with the addition of sodium hydroxide 1N and phosphoric acid 85%.
  • the aqueous solution was filtered through a single PVDF 0.22 pm sterilizing filter and the filtered solution was filled inside a grade C isolator and into a non-sterile 100 ml three-layer plastic bag (Fujimori’s/Zacros Nip ® - ⁇ Bag, also called MediTect ® IV Bag).
  • the headspace of the filled bags was flushed with nitrogen and then were sealed with a stopper and cap that was welded into place by using a Branson ultrasonic welder.
  • aqueous edaravone solution was analyzed before sterilization (see table 5). Samples were collected for the bulk sample, i.e. , before the filling of the bags:
  • the aluminum bag and the oxygen absorber 300cc Dry Pak ® were removed and the bags were placed in a second aluminum bag.
  • Heat-sterilization was then performed under atmospheric air by an autoclave cycle for 10 minutes at 123°C.
  • Impurity I content after heat-sterilization (t 0) and after stability under different conditions:
  • Impurity I can be detected in low amounts (0.03%) when the aqueous formulation of edaravone having about 0.40 ppm of oxygen is autoclaved.
  • the impurity content remains below 0.25% during stability and the amount of phenylhydrazine also remains below 300 ppm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un procédé de préparation d'une formulation d'édaravone ou d'un sel pharmaceutiquement acceptable de celui-ci, concrètement une formulation injectable aqueuse, qui contient de faibles quantités d'une certaine impureté. Ce procédé comprend la stérilisation à la chaleur d'une formulation aqueuse d'édaravone ou d'un sel pharmaceutiquement acceptable de celui-ci, qui comprend des anions bisulfites (HSO3-) et contient moins de 1 ppm d'oxygène.
PCT/EP2022/070466 2021-07-26 2022-07-21 Procédé de préparation de formulations d'édaravone WO2023006565A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21382689 2021-07-26
EP21382689.4 2021-07-26

Publications (1)

Publication Number Publication Date
WO2023006565A1 true WO2023006565A1 (fr) 2023-02-02

Family

ID=77168166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/070466 WO2023006565A1 (fr) 2021-07-26 2022-07-21 Procédé de préparation de formulations d'édaravone

Country Status (1)

Country Link
WO (1) WO2023006565A1 (fr)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0563845B2 (fr) 1984-05-18 1993-09-13 Olympus Optical Co
WO2008001496A1 (fr) 2006-06-28 2008-01-03 Fujimori Kogyo Co., Ltd. Récipient pour liquide
WO2009066752A1 (fr) 2007-11-22 2009-05-28 Mitsubishi Tanabe Pharma Corporation Récipient en plastique avec une couche de polyoléfine cyclique
WO2010016404A1 (fr) 2008-08-05 2010-02-11 藤森工業株式会社 Récipient pour liquide multicouche
JP2010081971A (ja) * 2008-09-29 2010-04-15 Terumo Corp エダラボンのプレミックス製剤
WO2010079693A1 (fr) 2009-01-06 2010-07-15 藤森工業株式会社 Orifice de versage, procédé pour sa production et récipient à liquide doté de l'orifice de versage
JP4596124B2 (ja) 2004-03-09 2010-12-08 藤森工業株式会社 医療用容器
CN102336710A (zh) 2011-07-11 2012-02-01 宁波大学 一种依达拉奉衍生物的合成方法
CN103083232B (zh) * 2013-01-30 2014-11-05 成都百裕科技制药有限公司 一种不加抗氧剂的依达拉奉注射液及其制备方法
CN106316957A (zh) 2015-06-15 2017-01-11 江苏正大丰海制药有限公司 一种依达拉奉杂质的中间体及其制备方法和用途
JP2018192643A (ja) 2017-05-12 2018-12-06 藤森工業株式会社 薬液収容プラスチック容器
CN110090225A (zh) 2019-04-19 2019-08-06 济南康和医药科技有限公司 一种依达拉奉氯化钠注射液及其制备方法
WO2019151532A1 (fr) 2018-02-05 2019-08-08 藤森工業株式会社 Stratifié et récipient en plastique
WO2019159967A1 (fr) 2018-02-15 2019-08-22 藤森工業株式会社 Récipient en plastique

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0563845B2 (fr) 1984-05-18 1993-09-13 Olympus Optical Co
JP4596124B2 (ja) 2004-03-09 2010-12-08 藤森工業株式会社 医療用容器
WO2008001496A1 (fr) 2006-06-28 2008-01-03 Fujimori Kogyo Co., Ltd. Récipient pour liquide
WO2009066752A1 (fr) 2007-11-22 2009-05-28 Mitsubishi Tanabe Pharma Corporation Récipient en plastique avec une couche de polyoléfine cyclique
WO2010016404A1 (fr) 2008-08-05 2010-02-11 藤森工業株式会社 Récipient pour liquide multicouche
JP2010081971A (ja) * 2008-09-29 2010-04-15 Terumo Corp エダラボンのプレミックス製剤
WO2010079693A1 (fr) 2009-01-06 2010-07-15 藤森工業株式会社 Orifice de versage, procédé pour sa production et récipient à liquide doté de l'orifice de versage
CN102336710A (zh) 2011-07-11 2012-02-01 宁波大学 一种依达拉奉衍生物的合成方法
CN103083232B (zh) * 2013-01-30 2014-11-05 成都百裕科技制药有限公司 一种不加抗氧剂的依达拉奉注射液及其制备方法
CN106316957A (zh) 2015-06-15 2017-01-11 江苏正大丰海制药有限公司 一种依达拉奉杂质的中间体及其制备方法和用途
JP2018192643A (ja) 2017-05-12 2018-12-06 藤森工業株式会社 薬液収容プラスチック容器
WO2019151532A1 (fr) 2018-02-05 2019-08-08 藤森工業株式会社 Stratifié et récipient en plastique
WO2019159967A1 (fr) 2018-02-15 2019-08-22 藤森工業株式会社 Récipient en plastique
CN110090225A (zh) 2019-04-19 2019-08-06 济南康和医药科技有限公司 一种依达拉奉氯化钠注射液及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHINA LICENSED PHARMACIST, vol. 11, no. 8, August 2014 (2014-08-01)
TANAKA MASAHIKO ET AL: "Stabilizers of edaravone aqueous solution and their action mechanisms. 1. Sodium bisulfite", J CLIN BIOCHEM NUTR, vol. 61, no. 3, 1 January 2017 (2017-01-01), pages 159 - 163, XP055978429, Retrieved from the Internet <URL:https://www.jstage.jst.go.jp/article/jcbn/61/3/61_17-61/_pdf/-char/en> *

Similar Documents

Publication Publication Date Title
EP3171868B1 (fr) Préparation de solution pour injection d&#39;acétaminophène conditionnée
JP6869899B2 (ja) 静脈内注入剤形
US20140303254A1 (en) Process Of Manufacturing A Stable, Ready To Use Infusion Bag For An Oxidation Sensitive Formulation
US20220233403A1 (en) Infusion bag of midazolam for intravenous use
KR20150132835A (ko) 변형된 가요성 플라스틱 용기에서 즉시 사용가능한 공용매 약학 조성물
EP3290025B1 (fr) Forme posologique de perfusion stable de la morphine
WO2015145911A1 (fr) Préparation pour injection et procédé de fabrication de celle-ci
JP6741286B2 (ja) 包装されたアセトアミノフェン注射液製剤の製造方法
JP2016022092A (ja) エダラボン含有プラスチック容器
JP2021175713A (ja) スガマデクス又はその薬理学的に許容される塩含有液剤
WO2023006565A1 (fr) Procédé de préparation de formulations d&#39;édaravone
US20230181495A1 (en) Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation
WO2021039084A1 (fr) Formulation d&#39;injection
AU2019257508A1 (en) Process of manufacturing a stable, ready to use infusion bag for an oxidation sensitive formulation
JP7182651B2 (ja) ビンカアルカロイド薬の投薬形態
BRPI0713639A2 (pt) método para a fabricação de uma formulação de ácido artesúnico intravenosa ou intramuscular, formulação de ácido artesúnico, kit para a produção de uma formulação de ácido artesúnico, métodos para tratar um paciente com malária, e para esterilização de ácido artesúnico em pó, e, formulação de ácido artesúnico
JP7512762B2 (ja) スガマデクス含有の液体製剤
JP2022035087A (ja) スガマデクス含有の液体製剤
WO2024008293A1 (fr) Compositions de phényléphrine injectables
EP4333792A1 (fr) Solution de dexmédétomidine dans un récipient de polyéthylène basse densité
BR112020007208A2 (pt) forma de dosagem de infusão intravenosa para pemetrexeda

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22753696

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE